Longeveron (LGVN) Stock Price, News & Analysis

Company Overview

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines intended to address serious and life-threatening conditions. Its lead product candidate, Lomecel-B, is an allogeneic medicinal signaling cell therapy derived from the bone marrow of healthy adult donors. The company is investigating the therapy for its potential to promote tissue repair, modulate inflammation and support blood-vessel formation.

Lomecel-B is being evaluated in clinical programs targeting hypoplastic left heart syndrome, an uncommon and severe congenital heart condition, as well as aging-related frailty and Alzheimer’s disease. Longeveron’s research focuses on the broader use of cell-based therapies in conditions for which existing treatment options are limited.

Founded in 2014 and headquartered in Miami, Florida, Longeveron conducts research and clinical development activities in the United States and has pursued programs involving international collaborators and clinical sites. The company is led by Chief Executive Officer Wa’el Hashad.

Key Stats

• Today's Range: $2.40 to $2.50
• 50-Day Range: $2.45 to $8.45
• 52-Week Range: $2.30 to $12.30
• Volume: 26,339 shs
• Average Volume: 222,271 shs
• Market Capitalization: $7.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $80.00
• Consensus Rating: Hold

Longeveron Stock Analysis - MarketRank™

Longeveron scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Longeveron has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Longeveron has a consensus price target of $80.00, representing about 3,199.0% upside from its current price of $2.43.

Amount of Analyst Coverage

Longeveron has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Longeveron is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Longeveron is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Longeveron has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.24% of the float of Longeveron has been sold short.

Short Interest Ratio / Days to Cover

Longeveron has a short interest ratio ("days to cover") of 4.65.

Change versus previous month

Short interest in Longeveron has recently decreased by 5.53%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Longeveron does not currently pay a dividend.

Dividend Growth

Longeveron does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 5 news articles for Longeveron this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added Longeveron to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Longeveron insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.42% of the stock of Longeveron is held by insiders.

Percentage Held by Institutions

10.01% of the stock of Longeveron is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LGVN
• CIK: 1721484
• Web: www.longeveron.com
• Phone: 305-302-7158
• Fax: N/A
• Employees: 38
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Longeveron: $80.00
• High Price Target: $80.00
• Low Price Target: $80.00
• Potential Upside/Downside: +3,219.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.70 million
• Net Margins: -1,977.59%
• Pretax Margin: -1,977.59%
• Return on Equity: -223.19%
• Return on Assets: -150.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.63
• Quick Ratio: 2.63

Sales & Book Value

• Annual Sales: $1.20 million
• Price / Sales: 6.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.47 per share
• Price / Book: 0.98

Miscellaneous

• Outstanding Shares: 3,190,000
• Free Float: 2,951,000
• Market Cap: $7.69 million
• Optionable: Not Optionable
• Beta: -0.19